Hormonal
Intensive glycemic control fails to significantly improve cardiovascular outcomes in patients with diabetes, whereas cholesterol-lowering therapy significantly reduces cardiovascular events regardless of baseline lipid profiles.
If you have diabetes, managing your blood sugar is crucial for preventing kidney and eye damage, but it will not significantly protect your heart. To reduce your risk of heart attack or stroke, you must prioritize lowering your LDL cholesterol, even if your levels appear 'normal' on a standard test. Statin therapy is the most effective intervention for cardiovascular prevention in diabetes, regardless of your baseline lipid levels.
Intensive glycemic control has essentially failed to significantly improve cardiovascular outcomes in clinical trials. ... there is strong evidence that cholesterol lowering improves cardiovascular outcomes, even in patients with apparently unremarkable lipid profiles.
Why this rating
Supported by multiple large-scale randomized controlled trials (DCCT, UKPDS, ACCORD, CARDS, HPS) and meta-analyses cited in the text.
Source
Diabetes Dyslipidemia
Jonathan Schofield et al. · Diabetes Therapy · 2016
DOI 10.1007/s13300-016-0167-x
More from this paper
- Statins are effective for primary and secondary prevention of cardiovascular disease in patients with diabetes, providing significant risk reduction even in patients with low baseline LDL cholesterol.Strong
- In patients with diabetes, LDL cholesterol concentration is a poor indicator of cardiovascular risk because it masks an increased number of atherogenic lipoprotein particles (high apoB) and the presence of small, dense LDL particles.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →